Healthcare stock prices have been pressured by election policy discussions and many believe share prices may continue to be impacted. Over the last three months (ending October 30, 2015), the overall S&P declined 1.4% while the S&P 500-Pharmaceuticals, Biotechnology and Life Sciences Index declined 6.1%, despite the defensive nature of the sector.
Stay Ahead with Kroll
Mergers and Acquisitions (M&A) Advisory
Kroll’s top ranked M&A Advisory practice spans sell-side, buy-side, due diligence, deal strategy and structuring, and capital raising.
Financial Sponsors Group
Dedicated coverage and access to M&A deal-flow for financial sponsors.
Transaction Advisory Services
Kroll’s Transaction Advisory Services platform offers corporate and financial investors with deep accounting and technical expertise, commercial knowledge, industry insight and seamless analytical services throughout the deal continuum.
Debt Advisory
Kroll has extensive experience raising capital for middle-market companies to support a wide range of transactions.